GUIDED THERAPEUTICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GUIDED THERAPEUTICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $767.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $98.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $81.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $102.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $36.0K | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $57.0K | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $244.0K | May 8, 2019 |
| FY2016 | Dec 31, 2016 | $0 | Mar 22, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $571.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $36.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($68.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $20.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $143.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($34.0K) | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | ($32.0K) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($286.0K) | May 8, 2019 |
| FY2017 | Dec 31, 2016 | $112.0K | Apr 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.49M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.34M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.07M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($279.0K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.92M) | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $1.02M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($10.70M) | May 8, 2019 |
| FY2017 | Dec 31, 2016 | ($3.97M) | Apr 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.37M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.33M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.36M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.05M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($937.0K) | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | ($1.55M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($3.12M) | May 8, 2019 |
| FY2017 | Dec 31, 2016 | ($3.82M) | Apr 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $469.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $526.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $228.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $77.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $69.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $143.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $122.0K | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $244.0K | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $334.0K | May 8, 2019 |
| FY2017 | Dec 31, 2016 | $733.0K | Apr 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.12M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.48M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.59M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.88M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($806.0K) | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | ($1.37M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($1.14M) | May 8, 2019 |
| FY2017 | Dec 31, 2016 | ($1.80M) | Apr 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $31.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $14.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 7, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.37M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.18M | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $236.0K | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $406.0K | May 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.49M | Apr 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.33M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.27M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.25M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $7.49M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $12.21M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $18.12M | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $16.06M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $19.81M | May 8, 2019 |
| FY2017 | Dec 31, 2016 | $10.76M | Apr 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.01M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($3.81M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($2.88M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($5.45M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($10.86M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($16.94M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($15.82M) | Apr 7, 2021 |
| FY2019 | Dec 31, 2017 | ($19.40M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2016 | ($9.27M) | May 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($157.06M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($153.71M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($151.12M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($147.36M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($142.39M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($139.96M) | Mar 30, 2022 |
| FY2020 | Sep 30, 2020 | $1.81M | Apr 7, 2021 |
| FY2020 | Jun 30, 2020 | $2.69M | Apr 7, 2021 |
| FY2020 | Mar 31, 2020 | $13.4K | Apr 7, 2021 |
| FY2020 | Dec 31, 2019 | ($139.56M) | Apr 7, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.31M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $643.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $182.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $899.0K | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 20, 2020 |
| FY2019 | Dec 31, 2017 | $1.0K | Apr 20, 2020 |
| FY2018 | Dec 31, 2016 | $14.0K | May 8, 2019 |
| FY2017 | Dec 31, 2015 | $35.0K | Apr 20, 2018 |
| FY2016 | Dec 31, 2014 | $162.0K | Mar 22, 2017 |
| FY2015 | Dec 31, 2013 | $613.0K | Mar 15, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $820.0K | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $23.0K | Mar 30, 2022 |
| FY2020 | Sep 30, 2020 | ($173.3K) | Apr 7, 2021 |
| FY2020 | Jun 30, 2020 | ($209.1K) | Apr 7, 2021 |
| FY2020 | Mar 31, 2020 | ($244.9K) | Apr 7, 2021 |
| FY2019 | Dec 31, 2019 | $5.71M | Apr 20, 2020 |
| FY2019 | Dec 31, 2018 | $5.07M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $7.96M | May 8, 2019 |
| FY2011 | Dec 31, 2011 | $4.0K | Mar 28, 2012 |
| FY2011 | Dec 31, 2010 | $31.0K | Mar 28, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | 1 | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | 997 | May 8, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | 0 | May 8, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 86.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 65.13M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 54.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 48.60M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 13.67M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 13.14M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 3,319 | Apr 7, 2021 |
| FY2019 | Dec 31, 2018 | 2,669 | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | 61,954 | May 8, 2019 |
| FY2017 | Dec 31, 2016 | 669 | Apr 20, 2018 |